A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled
Summary
Biotech firm Genmab saw its stock price double over the last three months following successful trials for its cancer treatments. These positive outcomes support the company's broader strategy to retain greater ownership of the pharmaceutical products it creates.
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
Source: Read the full story at US Top News and Analysis
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.